Introduction
Hematological changes occur quite frequently in patients with various malignant solid tumors [1] [2] [3] [4] [5] [6] and, as reported by some authors, may correlate significantly with patients' prognosis [4, [7] [8] [9] . Although the mechanisms responsible for these anomalies are still poorly understood, it is well known from in vitro and in vivo studies that both colony-stimulating factors and proinflammatory cytokines are essential in hematopoiesis and can also affect the number of neutrophils, lymphocytes and monocytes in the blood [2, 10, 11] .
Cytokines are a group of regulatory proteins, which act as mediators in the control of cell growth, survival and differentiation in various tissues in normal renewal, and repair of damage. They are produced by particular cells in response to appropriate stimuli [12] [13] [14] . In malignancy, various cytokines might be synthesized and released by tumor and stromal cells as well as by immune cells attracted to the tumor site [15] [16] [17] [18] . Cytokines are involved at every stage of tumor growth and dissemination, and act (combined with other factors) as autocrine-paracrine tumor growth factors. Elevated cytokine serum levels in cancer patients may have important prognostic value [17, [19] [20] [21] [22] [23] [24] . Moreover, it has been reported that high serum levels of interleukin 6 in cancer patients correlate with thrombocythemia [25, 26] , increased polymorphonuclear leukocyte and monocyte counts [27] , as well as with decreased hemoglobin [28] , and enhanced release of G-CSF from tumor cells may result in peripheral neutrophilia [2] . There are only a few reports about hematological changes and their relationship to cytokine serum levels [2, [29] [30] [31] [32] in such a rare group of malignant solid tumors as soft tissue sarcomas.
We have previously reported [33] that serum levels of several proinflammatory, proangiogenic and hematopoietic cytokines, as well as some of their soluble receptors, are frequently elevated in patients with various non-lymphoid malignant tumors, both of epithelial and mesenchymal origin. More than 50% of patients with soft tissue sarcomas who were included in the above study had increased serum levels of IL-6, IL-8, IL-10, IL-lra, M-CSF and sIL-2R, and 20% to 50% had increased serum levels of VEGF, bFGF, TNF RI, TNFRII, TNFot and G-CSF. Thirteen cytokines and their soluble receptors, which were selected for the present analysis, represent the major subtypes of cytokines (interleukins, tumor necrosis factor family members, hematopoietic colony-stimulating factors, chemokines, angiogenic factors) [12, 34] . It is also significant for the criteria of choice of analyzed cytokines that most of the selected cytokines are suspected of playing a role in the pathogenesis of other solid neoplasms [20] [21] [22] [35] [36] [37] .
The aim of this study was to evaluate the pretreatment routine hematological parameters in patients with untreated malignant soft tissue tumors and to correlate these results with serum levels of selected cytokines and clinicopathological features of the tumors. Special interest was paid to a possible prognostic significance of hematological tests in soft tissue sarcomas. Correlations between serum cytokine levels and clinicopathological features and survival of soft tissue sarcoma patients will be the subject of a separate report.
Patients and methods

Patients
Between April 1997 and December 1999, 145 patients with soft tissue sarcomas who underwent treatment in the Soft Tissue/Bone Sarcomas Department of the M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MSCMCCI) Warsaw, Poland, were enrolled into the study. There were 75 men and 70 women of mean age 49.9 ± 16.9 years (ranging from 18 to 80). All patients were selected on the basis of the following criteria: histologically proven soft tissue sarcoma, including primary tumors before treatment (74 cases) and locally recurrent tumors (71 cases) (all recurrences occurred more than three months after primary surgery). None of these patients had received prior radiotherapy or chemotherapy. At the time of presentation 113 patients had no distant metastases (M0) and 32 patients were in stage Ml with lung metastases. None of the patients had evidence of a primary myeloproliferative disorder. Patients had not undergone any other preliminary selection. Only patients who met with these conditions were included in the study. All of the patients provided informed consent in accordance with institutional regulatory requirements Peripheral blood samples were collected from all patients before treatment and from 50 healthy volunteers (26 male. 24 female; mean age 38.9 ± 15.1 years; range 19-71 years) without hematological abnormalities served as controls. The control group was fully comparable with the studied group of patients according to gender and age distribution. For serum cytokine evaluations a 30 ml blood specimen was obtained from each patient between 7.30 and 11.00 a.m. after overnight fasting. Sera were stored at -70 °C until analysis.
In all patients blood samples for routine blood tests were collected simultaneously.
Clinicopathological features of malignant soft tissue tumors were determined by physical examination, pathological examination of the primary lesion and routine imaging examination (chest X-ray, tumorcomputed tomography, ultrasonography of the abdominal cavity) at the time of blood collection. According to pathological examination there were 31 patients with liposarcomas (21.4%). 23 with synovial sarcomas (15.8%), 22 with malignant fibrous histiocytomas (MFH) (15 2% Table I .
Patients were stratified on the basis of tumor size (less and more than 10 cm according to the dichotomization suggested by Gustaflson [38] ) and tumor grade (Gl to G3 degree according to the standard histological criteria). Patients were also divided into two groups according to age: 1) younger =£49 years and 2) older >49 years (based on the mean age at the time of presentation in the studied group). The median patients follow-up time was 26.1 months.
The patients'clinical status was not known by the persons running cytokine and hematological assays, while assay results were not known to the surgeons recording the disease status.
Cytokine asssays
Sera were assayed for levels of 13 cytokines and soluble cytokine receptors with ELISA method using commercially available kits (R&D Systems, Minneapolis; Minnesota) according to the recommen-dations of the manufacturer. The levels of following 13 cytokines and cytokine receptors were measured: intcrleukin 6 (IL-6); interleukin 8 (1L-8); tumor necrosis factor a (TNFa); tumor necrosis factor receptor 1 (TNF RI); tumor necrosis factor receptor II (TNF R1I): soluble interleukin 2 receptor (sIL-2R), soluble interleukin 6 receptor (si L-6R); interleukin 1 receptor antagonist (lL-Ira); interleukin 10 (IL-10): vascular endothelial growth factor (VEGF): basic fibroblast growth factor (bFGF); granulocyte colony-stimulating factor (G-CSF); macrophage colony-stimulating factor (M-CSF). Reference values for each cytokine level were established in the Department of Tumor Markers from a study of 50 healthy volunteers and cut-off values were as follows (established on the basis of 5 and 95 percentile in the control group): IL-6 (0.7-2.4 pg/ml); IL-8 (10-12.5 pg/ml): TNFa (<4.4 pg/ml);TNF RI (600-1200 pg/ml); TNF Rll (1577-3500 pg/ml); siL-2R (758-1753 pg/ml); slL-6R (<55070 pg/ml); IL-lra (98-473 pg/ml), 1L-I0 (2.0-7.3 pg/ml); VEGF (< 325 pg/ml): bFGF (<4.4 pg/ml): M-CSF (100-600 pg/ml); G-CSF (7.0-34.0 pg/ml).
Hematological analyses
We have incorporated blood laboratory tests, which are a part of routine admission tests for all patients in MSCMCC. We evaluated the results of the following blood tests: hemoglobin level HGB (reference value: 11.0-18.0 g/dl), platelet count PLT (140-450 x IO 9 /1). white blood cell count WBC (4-10 x 10 9 /l), white blood cell differential count-neutrocyte count NE (2.3-6.6 x I0
9 /]). lymphocyte count LY (1.0-3.5 x |0 9 /l), monocyte count MN (0.1-0.8 x |0 9 /l), eosinophile count EO (0-0.5 x 10'Vl).
Statistical analysis
All statistical analyses were performed using STATIST1CA Software (StatSoft) with the Mann-Whitney U-test, Smirnov-Kolmogorov (only significant differences for both tests were considered significant) and x 2 test for comparison between two groups, where appropriate. We used the Kaplan-Meier method, log-rank test and multivariate Cox analysis for overall survival (OS) analysis. Differences at P < 0.05 were considered to be significant.
Results
Hematological test abnormalities
Of the 145 patients enrolled, one or more abnormal blood tests were found in 63 cases (43.4%).
The following blood test alterations were most frequent: neutrophilia (41 cases -28.3%), leucocytosis (40 cases -27.6%), decreased HGB (37 cases -25.5%), monocytosis (28 cases -19.3%) and thrombocytosis (21 cases -14.5%). Fifteen patients (10.3%) displayed decreased complete lymphocyte counts LY < 1.0 x 10 s */!. Eleven patients (7.6%) presented eosinophilia (EO > 0.5 x 1O 9 /1). Table 2 summarizes hematological data by tumor stage. We observed that PLT, WBC, NE and MN were significantly increased in more advanced stages of the tumors (size and grade) ( Figure 4 ). The PLT and NE counts were also significantly higher in Ml vs. M0 patients. HGB and LY correlated inversely only with the tumor size, while EO correlated with none of the clinicopathological features of studied tumors.
Taking into account all blood tests alterations -the percentage of patients with hematological disturbances was significantly higher in the group of patients with larger tumors > 10 cm (49 of 86 cases 57%) than in patients with smaller tumors < 10 cm (14 of 59 cases 23.7%) (P < 0.001).
We also found a significant inverse relationship between PLT and HGB. In the group of patients with thrombocytosis the mean hemoglobin level was: 10.14 ± 1.8 g/dl vs. 13.76 ± 2.7 g/dl {P < 0.001) in patients with normal platelet counts.
Cvtokine asssay results
Significant differences of serum levels of 11 of 13 cytokines (IL-lra, sIL-2R, IL-6, IL-8, IL-10, TNF RI, TNF RII, TNFa, M-CSF, bFGF, VEGF) (P < 0.001) were found in patients vs. controls (Table 3) . We found no significant changes in serum levels of sIL-6R and GCSF in patients vs. healthy subjects. Increased serum levels of IL-6 (69%),TNF RI (68%), IL-8 (60%) and TNF RII (58%) were most frequent in the analyzed group of patients. Elevated serum levels of complexity of several cytokines and soluble cytokine receptors (particularly: sIL-2R, IL-6, IL-8, MCSF, VEGF, TNFRI, TNFRII) correlated strongly with the most common abnormalities in hematological tests: neutrophilia, leukocytosis, monocytosis, thrombocytosis and anaemia (P < 0.001) (Table 4, Figure 2 ). It was also found that lymphopenia correlated significantly with increased serum levels of IL-6, sIL-2R and TNFRI (Figure 3) . No correlations were found between the most common hematological abnormalities and serum levels of TNFa and GCSF.
Survival analyses
At the time of this analysis, 56 patients from the studied group had died of the disease (38.6%). Median overall survival (OS) was 28.5 months. Average three-year OS, as calculated by the Kaplan-Meier method, was 49%.
In a univariate log-rank analysis we revealed that the five following factors correlated significantly with OS: tumor size (< and > 10 cm), tumor grade (Gl vs. G2-3), presence of metastatic disease (M0 vs. Ml), leukocytosis (< and > 10 x 10 9 /l), lymphopenia (< and > 1.0 x 10 9 /l) ( Figure 1 ) (P < 0.05).
However, in a multivariate survival analysis only the presence of metastases and tumor grade showed statistical significance.
Discussion
Oncologists often come across clinical conditions which are accompanied by changes in the number of blood cells. Secondary hematological abnormalities are a common feature of malignant disease [1-3, 7, 39, 40] . Analysis of differences in whole blood cell composition between cancer patients and healthy subjects may provide a better understanding of neoplastic disease. The mechanisms of peripheral hematological changes in patients with various malignant tumors may be complex and are still poorly understood. Hematopoietic and proinflammatory cytokines as well as their free receptors and antagonists may be primarily involved in these changes, since their role in normal hematopoiesis has been well documented both in in vino and in vivo studies [11] . Cytokines, considered crucial factors in hematopoiesis, may act as positive (e.g., IL-6, IL-11, GM-CSF) or negative (e.g., the transforming growth factor TGFfS) regulators of differentiation, maturation and growth of the hematopoietic cells [41, 42] . In a wide sense hematopoietic cytokines include not only typical growth factors (e.g., erythropoietin, G-CSF, M-CSF), but also various cytokines (e.g., IL-6,TNFcc, macrophage inflammatory protein MIP-lot) [43, 44] , which were identified by other activities not connected with hematopoiesis. The function of hematopoietic growth factors is not only limited to cell lines. These multiple cytokines involved in hematopoiesis create an extremely complicated cytokine network and demonstrate multifunctional, overlapping activity [11, 44] . Important biological effects and immunological implications of the particular cytokines can be reflected in routine blood test abnormalities.
The synthesis and secretion of cytokines has been well documented in many human malignant solid tumors and several reports have demonstrated their enhanced levels in sera of patients with various malignancies [14, 18, 19, 24, 29, 37, 45] . However, only a few reports have addressed this problem in soft tissue sarcomas [2, [30] [31] [32] . To the best of our knowledge, our present report is the first attempt to look for correlations between various hematological abnormalities with serum levels of a larger variety of cytokines and free cytokine receptors in a large series of patients with soft tissue sarcomas. Special interest was also paid to the possible prognostic value of routine blood tests in the soft tissue malignant tumor group.
It is important to emphasize that many statistical computations could distort the results of the study. In order to improve the reliability of statistical analyses only significant differences for both applied tests were considered significant for comparisons between the two groups.
We revealed the different serum levels of several cytokines and cytokine receptors in healthy and sarcoma patients, thus supporting the thesis about their role in the pathogenesis of sarcomas. Moreover, cytokine levels and disease stage were strongly dependent (data to be published elsewhere). We have found that the most common hematological abnormalities seen in our patients, that is low hemoglobin level as well as high white blood cell, neutrophile, monocyte and thrombocyte counts, correlated very strongly with elevated serum levels of several cytokines and cytokine receptors, in particular of IL-6, IL-8, M-CSF, VEGF, sIL-2R, TNF RI and TNF RII. We failed to identify any single cytokine responsible for most of the changes in whole blood cell counts. It is worthwhile to stress that G-CSF levels, which can physiologically increase the number and activity of neutrophils, had no relationship with neutrophil count. This observation remains consistent with data of other authors [46] , who demonstrated that the neutrophils to lymphocytes (N/L) ratio was related to sIL-2R levels, but not to G-CSF levels. Thrombocytogenesis is regulated by multiple humoral factors [47, 48] , but IL-6 is thought to the most potent stimulator of platelet formation, also in cancer patients [25, 28, 49, 50] . However, it has been proved that other factors, e.g., M-CSF and erythropoietin, play a role in the stimulation of thrombopoiesis. TNFoc is known to depress erythropoiesis anemia, and response of the host in the form of increased erythropoietin production may have influence on the increased platelet count [51] . All these cytokines, with the notable exception of TNFoc, were found to be related to thrombocytosis in our study.
Lymphocytopenia, which was seen less frequently in soft tissue sarcoma patients, correlated with enhanced IL-6, sIl-2R and TNF RI serum levels. Blay et al. found a relationship between lymphopenia and elevated plasma levels of IL-6 and VEGF [52] . We also observed that increased levels of IL-6 -multifunctional and pleiotropic cytokine -were related to decreased lymphocyte count and noted a similar relationship for sIL-2R and TNF RI serum levels. It was also previously suggested that sIL-2R may suppress the function of T lymphocytes [46] .
In general, our data suggest that the imbalance involving several cytokines and cytokine receptors, frequently occurring in cancer patients, may be one of the major mechanisms of hematological abnormalities developing in the course of tumor growth and progression. Since, in most patients with soft tissue sarcomas the serum levels of proinflammatory, hematopoietic and proangiogenic cytokines are elevated in parallel, it is very likely that they may synergize in influencing blood cell counts. There is ample evidence that several cytokines of various primary defined functions are in fact pleiotropic and are frequently released sequentially in response to appropriate stimuli.
In our study we observed different hematological abnormalities in about 40 % of patients with soft-tissue sarcomas, without evidence of a concomitant primary myeloproliferative disorder or any other condition (e.g., infection), except the malignant disease, to explain these disturbances. Patients with more advanced disease showed a tendency toward more frequent occurrence of hematological anomalies. These differences reached statistical significance. The most common anomaly was an increased number of blood leukocytes, mainly neutrophils. It was noted by Satomi et al. [46] that in advanced colorectal cancer the neutrophils to lymphocytes ratio (N/L) was significantly increased. Our findings have also shown that WBC and NE increased with malignant soft tissue sarcoma stage, while the number of lymphocytes was diminished. Neutrophilia in disseminated cancer patients is commonly connected with decreased marrow granulocyte reserve [4] , It was also reported that neutrophils might promote cancer growth and progression [8] . Leukocytosis was a univariate unfavorable prognostic factor, as earlier reports demonstrated in some other neoplasms [7, 40] . However, in multivariate analyses this variable lost its significance. Similarly, other routine blood tests used seem to be of no significant value in predicting the survival in soft tissue sarcoma patients. In multivariate analyses only well-established prognostic factors (tumor grade and presence of lung metastases) proved their significance for predicting the overall survival in soft tissue sarcoma patients.
Apart from the leukocytosis and neutrophilia, a few other hematological changes were recorded in the present study. Among these decreased hemoglobin level and thrombocytosis are also rather frequently recorded hematological disturbances [1, 8, 28, 39, 49, 53, 54] in cancer patients. An inverse relationship between the hemoglobin level and the platelet count has been found in sarcoma patients, and these abnormalities appeared to occur more frequently in patients with more advanced sarcomas. It has been demonstrated that increased platelet count may indicate unfavorable prognosis [9, 55, 56] . A very valuable study was presented by van der Zee et al. [28] , who demonstrated that high pretreatment platelet count was a negative prognostic factor in patients with ovarian cancer. However, there are also contrary reports about the prognostic role of thrombocytosis in cancer patients [57, 58] . As mentioned previously, we also failed to find thrombocytosis as a reliable prognostic factor in the presented study. A significant increase in monocyte count was found in our group of patients. Some authors recorded a relationship between monocyte count elevation and shorter survival in malignancy [40] . An increase in eosinophil count was a very rare finding in our studywe detected it in only about 7% of patients. It has been suggested that disseminated cancer (independent from the histologic type of the tumor) may be accompanied by marked blood eosinophilia [59] . Eosinophilia is considered as an ominous sign reflecting malignancy aggressiveness. We found no support for these suggestions in our data.
Special interest was directed to lymphocyte count. Significantly lower values of lymphocytes were detected in 10% of patients and were related to increased tumor burden. This has also been seen in cancers of various origin [60] . It was suggested that the low lymphocyte count can indicate immunodeficiency status in cancer patients. Increased numbers of circulating CD8+ (suppressor) T cells are a common feature in cancer patients [61] . Blay et al. [62, 63] demonstrated the value of lymphopenia as a predictor of the toxicity of chemotherapy. The same authors have recently reported that pretreatment lymphocytopenia (defined as LY < 1.0 x 10 y /l) [52] is related to more aggressive behavior of tumor and may be an independent unfavorable prognostic factor for survival in soft-tissue sarcomas. In our series we observed that lymphocyte count <l.0x 1O 9 /1 correlated with poorer survival but this relationship was significant only in univariate analysis (Figure 1 ). This discrepancy may be due in part to the higher incidence of advanced stages of the disease in the series of Blay et al. [52] . Lymphocytopenia -as a marker of cancer progression -may only be used as an additional, complementary factor which helps to distinguish low and high-risk soft tissue sarcoma patients.
In conclusion, our results demonstrate that significant alterations in whole blood cell counts and leukocyte differentials are rather commonly found in soft tissue sarcoma patients, particularly in more advanced stages. However commonly recorded hematological analyses, when compared to well-known prognostic factors, have a limited predictive value in soft tissue sarcoma patients. Strong correlations between the presence of several hematological abnormalities and serum levels of several cytokines, suggest that the former may develop as a result of cytokine misbalance frequently occurring in soft tissue sarcoma patients.
